Astellas Receives Positive CHMP Opinion for VEOZA (fezolinetant)
Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Oct 23
Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 Oct 23
Zynerba Pharmaceuticals stands at the forefront of producing pharmaceutical-grade transdermal cannabinoid therapies specifically tailored for orphan neuropsychiatric disorders
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Oct 23
Through the acquisition, BMS will add Mirati’s lung cancer drug Krazati to its commercial portfolio, along with several…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Oct 23
The acquisition will strengthen Kyowa Kirin’s portfolio with several HSC gene therapies targeting serious diseases, maximise the value…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Oct 23
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Oct 23
The potential development program reflects PharmaEssentia’s efforts to diversify its current expertise and expand its pipeline with a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Sep 23
Intercept is engaged in developing and commercialising novel therapeutics for rare and serious liver diseases, and its acquisition…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Sep 23
Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Sep 23
Under the licensing agreement, RefleXion will develop and commercialise RXM-4768 molecule to direct its SCINTIX biology-guided radiotherapy
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Sep 23
CEPI will contribute up to $90m funding for the partnership, which will support the development of mRNA-based vaccine…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates